A global healthcare and life science company drives value in private and public companies through operational and strategic direction as well as patient capital. The firm is headquartered in Western Europe and has an additional office in the USA. Given its structure and source of capital, the firm can acquire interests in early and late stage ventures without restriction on the location of opportunities. As a public company, the firm is a source of permanent capital. Average initial stakes range from $5M – $15M in the form of equity, with additional capital reserved for follow-on investments, The firm prefers to have a Board position in order to actively support the companies in which it invests.
The firm is focused on areas of unmet medical need, strongly favoring breakthrough and cutting-edge technologies over iterative or symptomatic treatments. The firm has particular interests in oncology (especially immuno-oncology), cardiovascular, metabolic, neuroscience indications, anti-infectives, gene therapy, and orphan diseases, as well as other therapeutic areas. The firm invests across the life cycle of development, from company formation through to companies with marketed products.
The firm is open to working with a variety of companies and entrepreneurs, but prefers management teams who have prior experience in the specific stage of development (clinical development, commercial strategy, etc.) and indication/area of their current venture. The firm also looks for startups companies with a strong BOD, SAB and support network (legal, back office, KOLs, etc.), though these are not prerequisites.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply